Parkinson's apathy drug trial stalls after just 8 patients

NCT ID NCT05182151

Terminated Symptom relief Sponsor: Medical University of South Carolina Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether istradefylline, a drug already approved for motor symptoms in Parkinson's, could also improve apathy and motivation. Only 8 people enrolled before the trial was terminated early. The results are too limited to draw any conclusions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Istradefylline
What this could lead to: If it worked, this could point toward a treatment for apathy in Parkinson's disease, helping people feel more motivated and engaged.
What could go wrong: The trial was terminated early and only enrolled 8 people, so we have very little data. It is unclear if istradefylline helps with apathy, and results may not apply to others.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for APATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Lethargy Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

APATHY PARKINSON DISEASE

Contacts and locations

Locations

MUSC Movement Disorders Program

Charleston, South Carolina, 29425, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.